RU2013147810A - Способы целенаправленного лечения лобно-височной лобарной дегенерации - Google Patents
Способы целенаправленного лечения лобно-височной лобарной дегенерации Download PDFInfo
- Publication number
- RU2013147810A RU2013147810A RU2013147810/15A RU2013147810A RU2013147810A RU 2013147810 A RU2013147810 A RU 2013147810A RU 2013147810/15 A RU2013147810/15 A RU 2013147810/15A RU 2013147810 A RU2013147810 A RU 2013147810A RU 2013147810 A RU2013147810 A RU 2013147810A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- oxazepin
- hydroxybenzamide
- dibenzo
- hydroxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 48
- 230000007850 degeneration Effects 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 claims abstract 42
- -1 -OH Chemical group 0.000 claims abstract 37
- 125000001424 substituent group Chemical group 0.000 claims abstract 31
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 28
- 125000005843 halogen group Chemical group 0.000 claims abstract 24
- 125000000217 alkyl group Chemical group 0.000 claims abstract 20
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 20
- 150000002367 halogens Chemical class 0.000 claims abstract 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 17
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- 125000003118 aryl group Chemical group 0.000 claims abstract 11
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 11
- 150000003839 salts Chemical class 0.000 claims abstract 11
- 239000000203 mixture Substances 0.000 claims abstract 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims abstract 7
- 125000004404 heteroalkyl group Chemical group 0.000 claims abstract 5
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims abstract 4
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 claims 40
- 125000005605 benzo group Chemical group 0.000 claims 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 12
- 108700028369 Alleles Proteins 0.000 claims 9
- 108010012809 Progranulins Proteins 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 102000019204 Progranulins Human genes 0.000 claims 3
- 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 2
- SWYHUULPITWRBP-UHFFFAOYSA-N 4-(11-cyclopropyl-8-fluorobenzo[b][1,4]benzodiazepin-6-yl)-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1C(C1=CC(F)=CC=C11)=NC2=CC=CC=C2N1C1CC1 SWYHUULPITWRBP-UHFFFAOYSA-N 0.000 claims 2
- PFSXJBFAWJVMPP-UHFFFAOYSA-N 4-(11-cyclopropylbenzo[b][1,4]benzodiazepin-6-yl)-n-hydroxy-n-methylbenzamide Chemical compound C1=CC(C(=O)N(O)C)=CC=C1C(C1=CC=CC=C11)=NC2=CC=CC=C2N1C1CC1 PFSXJBFAWJVMPP-UHFFFAOYSA-N 0.000 claims 2
- SKDLHAAUIUFOBJ-UHFFFAOYSA-N 4-(11-cyclopropylpyrido[2,3-b][1,5]benzodiazepin-5-yl)-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1C(C1=CC=CN=C11)=NC2=CC=CC=C2N1C1CC1 SKDLHAAUIUFOBJ-UHFFFAOYSA-N 0.000 claims 2
- QTGGHMCAFOOZEY-UHFFFAOYSA-N 4-(11-ethylbenzo[b][1,4]benzodiazepin-6-yl)-n-hydroxybenzamide Chemical compound C12=CC=CC=C2N(CC)C2=CC=CC=C2N=C1C1=CC=C(C(=O)NO)C=C1 QTGGHMCAFOOZEY-UHFFFAOYSA-N 0.000 claims 2
- SYXIDWBYJFWNJQ-UHFFFAOYSA-N 4-(11-ethylpyrido[2,3-b][1,5]benzodiazepin-5-yl)-n-hydroxybenzamide Chemical compound C12=CC=CN=C2N(CC)C2=CC=CC=C2N=C1C1=CC=C(C(=O)NO)C=C1 SYXIDWBYJFWNJQ-UHFFFAOYSA-N 0.000 claims 2
- BLMRWAZWBZJUFF-UHFFFAOYSA-N 4-(11h-benzo[b][1,4]benzodiazepin-6-yl)-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1C1=NC2=CC=CC=C2NC2=CC=CC=C12 BLMRWAZWBZJUFF-UHFFFAOYSA-N 0.000 claims 2
- QIPJDHBKKRZLEH-UHFFFAOYSA-N 4-(3-chloro-11H-benzo[b][1,4]benzodiazepin-6-yl)-N-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QIPJDHBKKRZLEH-UHFFFAOYSA-N 0.000 claims 2
- IQFRWAOSBZHQMX-UHFFFAOYSA-N 4-[(benzo[b][1,4]benzoxazepin-6-ylamino)methyl]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CNC1=NC2=CC=CC=C2OC2=CC=CC=C12 IQFRWAOSBZHQMX-UHFFFAOYSA-N 0.000 claims 2
- WFQIYDSBYXEJKZ-UHFFFAOYSA-N 4-[2-(benzo[b][1,4]benzoxazepin-6-ylamino)ethyl]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CCNC1=NC2=CC=CC=C2OC2=CC=CC=C12 WFQIYDSBYXEJKZ-UHFFFAOYSA-N 0.000 claims 2
- JVDCTJQKJALJKL-UHFFFAOYSA-N 4-[[(11-cyclopropylbenzo[b][1,4]benzodiazepin-6-yl)amino]methyl]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CNC(C1=CC=CC=C11)=NC2=CC=CC=C2N1C1CC1 JVDCTJQKJALJKL-UHFFFAOYSA-N 0.000 claims 2
- HDAIRFRHDIODJQ-UHFFFAOYSA-N 6-[(4-benzo[b][1,4]benzoxazepin-6-ylphenyl)methylamino]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound C1=CC=CC2=C1C(=N/C1=C(O2)C=CC=C1)C1=CC=C(CNC2C(C(C(C(O2)C(=O)O)O)O)O)C=C1 HDAIRFRHDIODJQ-UHFFFAOYSA-N 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- GSHJNEGTRIPBPA-UHFFFAOYSA-N n-hydroxy-4-(11h-pyrrolo[2,1-c][1,4]benzodiazepin-6-yl)benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1C1=NC2=CC=CC=C2CN2C1=CC=C2 GSHJNEGTRIPBPA-UHFFFAOYSA-N 0.000 claims 2
- KTSOHMXHVGZAPO-UHFFFAOYSA-N pyrido[4,3-f][1,4]oxazepine Chemical compound O1C=CN=CC2=CC=NC=C12 KTSOHMXHVGZAPO-UHFFFAOYSA-N 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 0 C*(C)(C(c(cc1)ccc1C1=*c2ccccc2Oc2c1cccc2**)=O)OC Chemical compound C*(C)(C(c(cc1)ccc1C1=*c2ccccc2Oc2c1cccc2**)=O)OC 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467989P | 2011-03-26 | 2011-03-26 | |
| US61/467,989 | 2011-03-26 | ||
| PCT/US2012/030527 WO2012135097A1 (en) | 2011-03-26 | 2012-03-26 | Methods of targeted treatment of frontotemporal lobar degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013147810A true RU2013147810A (ru) | 2015-05-10 |
Family
ID=45931040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013147810/15A RU2013147810A (ru) | 2011-03-26 | 2012-03-26 | Способы целенаправленного лечения лобно-височной лобарной дегенерации |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140179678A1 (https=) |
| EP (1) | EP2691099A1 (https=) |
| JP (2) | JP5995956B2 (https=) |
| CN (2) | CN103561747B (https=) |
| AR (1) | AR085572A1 (https=) |
| AU (1) | AU2012236852A1 (https=) |
| CA (1) | CA2831291A1 (https=) |
| IL (1) | IL228405A0 (https=) |
| MX (1) | MX2013011096A (https=) |
| RU (1) | RU2013147810A (https=) |
| TW (1) | TW201247205A (https=) |
| UY (1) | UY33973A (https=) |
| WO (1) | WO2012135097A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10149836B2 (en) | 2014-03-21 | 2018-12-11 | The Board Of Regents Of The University Of Texas System | Isoxazole treatments for frontotemporal dementia |
| US10189841B2 (en) | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| AR119149A1 (es) * | 2019-06-12 | 2021-11-24 | Arkuda Therapeutics | Derivados de isoquinolina como moduladores de la progranulina |
| US20230201269A1 (en) * | 2020-04-24 | 2023-06-29 | Spinalcyte, Llc | Treatment of frontotemporal dementia using fibroblasts and products thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
| CN101573333B (zh) * | 2006-10-28 | 2013-06-12 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| US20090291444A1 (en) * | 2008-03-31 | 2009-11-26 | Jason Eriksen | Methods and materials for detecting and treating dementia |
| US20110288070A1 (en) * | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2009137499A1 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
-
2012
- 2012-03-26 AR ARP120101007A patent/AR085572A1/es unknown
- 2012-03-26 JP JP2014502654A patent/JP5995956B2/ja not_active Expired - Fee Related
- 2012-03-26 MX MX2013011096A patent/MX2013011096A/es not_active Application Discontinuation
- 2012-03-26 CN CN201280025073.5A patent/CN103561747B/zh not_active Expired - Fee Related
- 2012-03-26 CN CN201610143729.3A patent/CN105748484A/zh active Pending
- 2012-03-26 TW TW101110441A patent/TW201247205A/zh unknown
- 2012-03-26 EP EP12712497.2A patent/EP2691099A1/en not_active Withdrawn
- 2012-03-26 US US14/007,572 patent/US20140179678A1/en not_active Abandoned
- 2012-03-26 CA CA2831291A patent/CA2831291A1/en not_active Abandoned
- 2012-03-26 WO PCT/US2012/030527 patent/WO2012135097A1/en not_active Ceased
- 2012-03-26 RU RU2013147810/15A patent/RU2013147810A/ru not_active Application Discontinuation
- 2012-03-26 UY UY0001033973A patent/UY33973A/es not_active Application Discontinuation
- 2012-03-26 AU AU2012236852A patent/AU2012236852A1/en not_active Abandoned
-
2013
- 2013-09-12 IL IL228405A patent/IL228405A0/en unknown
-
2016
- 2016-08-23 JP JP2016162758A patent/JP2017019826A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201247205A (en) | 2012-12-01 |
| JP2014511848A (ja) | 2014-05-19 |
| CN103561747A (zh) | 2014-02-05 |
| IL228405A0 (en) | 2013-12-31 |
| JP5995956B2 (ja) | 2016-09-21 |
| EP2691099A1 (en) | 2014-02-05 |
| CN105748484A (zh) | 2016-07-13 |
| CA2831291A1 (en) | 2012-10-04 |
| US20140179678A1 (en) | 2014-06-26 |
| AU2012236852A1 (en) | 2013-09-26 |
| CN103561747B (zh) | 2016-04-06 |
| MX2013011096A (es) | 2014-06-06 |
| WO2012135097A1 (en) | 2012-10-04 |
| AR085572A1 (es) | 2013-10-09 |
| JP2017019826A (ja) | 2017-01-26 |
| UY33973A (es) | 2012-10-31 |
| NZ615177A (en) | 2016-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6434416B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| AU2009324495B2 (en) | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles | |
| RU2009120048A (ru) | Способы и комбинированные средства для лечения болезни альцгеймера | |
| JP2010508296A5 (https=) | ||
| RU2010148762A (ru) | Тетразольные соединения для снижения концентрации мочевой кислоты | |
| RU2013155586A (ru) | [1,3]оксазины | |
| RU2015121424A (ru) | Комбинированная терапия | |
| RU2012117796A (ru) | Производные пиразолиндиона как ингибиторы надфн-оксидазы | |
| RU2009136592A (ru) | Терапевтические агенты | |
| RU2013147810A (ru) | Способы целенаправленного лечения лобно-височной лобарной дегенерации | |
| RU2005136370A (ru) | Трициклические индоловые производные и их применение в лечении болезни альцгеймера | |
| RU2010135253A (ru) | Агонисты мускариновых рецепторов, композиции и способы лечения с их применением и способы их получения 177 | |
| RU2008125040A (ru) | ПРОИЗВОДНЫЕ АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1.5-a]ПИРИДИНА | |
| RU2333209C9 (ru) | Композиции и способы для борьбы с дисфункциями нижних мочевых путей с использованием агонистов дельта-опиоидных рецепторов | |
| JP2014511848A5 (https=) | ||
| JP2002532503A5 (https=) | ||
| JP2005508969A5 (https=) | ||
| RU2014105177A (ru) | Новое соединение, проявляющее ингибиторную активность в отношении parp | |
| US20190022091A1 (en) | Method of treatment for mental disorders | |
| RU2004120556A (ru) | Производные 4-пиперидинилалкиламина в качестве антагонистов мускариновых рецепторов | |
| RU2007114763A (ru) | Галогенозамещенные производные бензодиазепинов | |
| RU2010151143A (ru) | Замещенные хиназолины | |
| CZ2004524A3 (cs) | Agonisté nikotinového acetylcholinového receptoru v léčbě syndromu neklidných nohou | |
| US20070299048A1 (en) | Combination of Gaboxadol and 5Ht2 Antagonists | |
| WO2008021432A2 (en) | Compositions and methods for treatment of conditions affecting the nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161124 |